ArticleBMC cancer2017

A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer.

Kerry Lynn Reynolds et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.